This document summarizes a presentation given at the J.P. Morgan 26th Annual Healthcare Conference. It discusses Wyeth's financial performance in Q3 and the first nine months of 2007, with revenue and earnings growth across key franchises like Enbrel, Effexor, Prevnar, and Protonix. It also highlights Wyeth's approved, pending, and upcoming opportunities, including new data on drugs like Pristiq, Torisel, and expanded indications for Prevnar 13. Wyeth expects continued growth from these pharmaceutical products and advancing its oncology pipeline.
1) Valeant reported strong third quarter 2012 results with total revenue of $884 million, up 47% from the third quarter of 2011, and cash EPS of $1.15, up 74% year-over-year.
2) The company's past acquisitions continue to perform well or exceed expectations, with most acquisitions achieving revenue CAGRs of 10-30% above forecasted levels.
3) Management provided an update on the pending Medicis acquisition and efinaconazole development program and reaffirmed 2012 financial guidance during the conference call discussing the company's third quarter results.
This document provides an overview of TXU's first quarter 2006 earnings discussion. It highlights improved operational earnings compared to the first quarter of 2005, driven by record production levels at TXU Power's lignite and nuclear units. It also summarizes new electricity product offerings introduced by TXU Energy in North Texas to establish TXU as the leader among Texas incumbents. Additionally, it outlines six key drivers of attractive returns for TXU's clean coal investment program and how hedging protects a portion of the value while retaining upside potential from commodity price moves.
The document summarizes the company's financial results for the third quarter of 2007. It reported 6% revenue growth and 1% growth in operating profit. Earnings per share were up 9%. The company also saw a 13% increase in cash flow. For full-year 2007, the company is projecting mid-single digit growth in internal net sales and low single-digit growth in internal operating profit. It is raising its earnings per share guidance. For 2008, the company expects more sustainable growth.
The document provides a safe harbor statement for any forward-looking statements made in the presentation. It notes that actual results could differ materially from projected results due to general economic conditions, competitive factors, legislative or regulatory changes, and other risks. The presentation agenda includes discussing Unum Group's business, 4Q-2007 results, how the company has changed, and its outlook. Financial guidance is provided for 2008 earnings per share, return on equity, capital position, and long-term trends through 2009 and beyond.
The document provides an overview of Kellogg Company's financial results for the first quarter of 2008, including:
1) Net sales increased 10% year-over-year, with 5% internal growth driven by price increases, product mix, and volume.
2) Operating profit grew 9% year-over-year, with 6% internal growth achieved through productivity savings and price increases despite higher costs.
3) Guidance for full-year 2008 forecasts mid-single digit growth in internal net sales and operating profit, with EPS of $2.92 to $2.97 despite cost pressures and investments in innovation.
- The document reports on Monsanto's financial results for the second quarter of 2008, projecting continued strong earnings growth, margins, and cash generation.
- Key highlights included a projected 58-63% increase in ongoing earnings per share, gross profit margins reaching 53% (two years ahead of target), and over $1.3 billion in free cash flow.
- Monsanto expected its seeds and traits business to double gross profits from 2007 to 2012 through new product launches and increased seed and trait penetration globally.
Paraná Banco reported its financial results for 4Q08 and full year 2008. Key highlights include:
- Net income of R$84.1 million in 2008, with the insurance sector contributing 27.2%
- Total assets of R$1.9 billion, growing 5.1%
- Origination of payroll-deductible
The document summarizes Unum Group's fourth quarter 2007 results and provides an overview of the company. Key points include:
- Fourth quarter profits increased 15.8% year-over-year and the group disability benefit ratio declined.
- Unum US had strong sales growth while Unum UK sales declined due to legislative changes in the prior year.
- Colonial continued favorable benefit ratio trends and higher sales.
- Unum Group has diversified its earned premium base across business segments and geographies compared to prior years.
This document summarizes Pfizer's fourth quarter 2007 earnings teleconference. It reports that Pfizer exceeded its 2007 revenue and EPS guidance. Key highlights included:
- Revenue increased 4% year-over-year in Q4 2007 and 1% for full year 2007. Adjusted diluted EPS increased 21% in Q4 2007 and 7% for full year.
- New products like Chantix, Lyrica and Sutent grew substantially and partially offset declines from products that lost exclusivity.
- 2008 guidance was increased, with revenue range increased and bottom end of EPS guidance also increased.
- Cost reduction initiatives continued to reduce expenses, with further savings expected in 2008.
Energias do Brasil reported its 1Q06 earnings results. Key highlights included growth in energy distributed and net revenues, with improvements in operational efficiency. Investments in distribution and generation resumed, and financial performance was strengthened by efficient debt management. Shares performed well since the IPO, reflecting the company's value-focused business model and strategic consistency.
This document summarizes news from the biotech industry, including:
1) Rumors that Sanofi has offered $18.7 billion, or $70 per share, to acquire Genzyme Corp, a 30% premium over Genzyme's stock price. Whether this fully values Genzyme is debated.
2) Celgene Corp beat earnings estimates on strong Revlimid sales and acquired Abraxis BioScience for $2.9 billion.
3) Ireland plans to offer $323 million to attract top U.S. venture capital funds to establish bases in Ireland and invest in local biotech firms.
The Connected User - iCrossing Client Event May 2010iCrossing
The document discusses the evolution of the web and connected users. It describes how the web has changed from static brochure-like Web 1.0 to more social and user-centered Web 2.0 and the potential for a semantic Web 3.0 driven by social graphs and user data. It also examines how search is shifting from a link-based model to prioritizing social relationships and conversations, with companies needing to understand where their customers are online and how to build connections to better engage with them.
This document lists 5 projects: an app for canned tuna company Greenpeace, an annual report for Tourism Australia, a youth brand for Tourism Australia, an identity and website for furniture company Möbelstuck, and an illustrated map and design project for Tourism Australia.
Search Becomes the Display OS
Search Engine Strategies Conference London
18 February 2010
Presented by Dax Hamman, Vice President, Display Media, iCrossing
Twitter: @daxhamman
The document summarizes the history of pollution in Lake Erie and efforts to reduce phosphorus levels. It identifies key causes of pollution over time, including sediment, sewage, overfishing, chemicals, nutrients, and invasive species. Sources of phosphorus include land use, discharges, resource exploitation, and invasive species introduction. Agriculture is identified as a key nonpoint source of phosphorus, though levels of inputs from fertilizer, manure, and biosolids have decreased. Recommendations focus on improving nutrient management practices in agriculture to reduce dissolved reactive phosphorus runoff. Ongoing monitoring and research aim to evaluate the impacts of changes and ensure phosphorus reductions are achieved.
People in today's on-the-go world rely on mobile devices for accessing a variety of information. Mobile consumption of Web properties is on track to overtake conventional desktop access by 2013. To achieve optimal customer engagement, enterprises need to focus on Web engagement for the mobile channel now more than ever before.
This presentation explores how mobile can be seamlessly woven into a Web engagement strategy, how to effectively deliver content across a multi-channel infrastructure with a particular emphasis on mobile devices, and how Alfresco and Crafter rivet can make it happen.
This document discusses findings from a study on how millennials and older shoppers use mobile devices while shopping in stores. Some key findings include:
- Nearly 50% of US consumers have smartphones and use them while shopping, with millennials and older "shopptimizers" using phones most of the time in stores.
- People use their phones in stores for various purposes like checking prices, reading reviews, making lists, and showrooming (researching items in stores then buying online).
- Over 40% said their phone influenced a purchase decision during their last store visit.
- Showrooming is common, with nearly half of millennials buying something online within the last month after visiting stores.
Social Media and the Law - by Tom CowlingiCrossing
Social Media Law: Branded content, conversations and the new responsibilities of marketers online
Brands are becoming publishers, participants and distributors on the social web. What do they need to bear in mind from a legal perspective?
In partnership with Wired Sussex.
Presented at the OEC's Legislative Summit 2012. by Jennifer Doron.
By now we are all familiar with social media. The names at least: Facebook, Twitter, Foursquare, LinkedIn, and hundreds more.
But how do we harness the numbers of people engaged online - and their incredible power - to produce positive, lasting change for the environment?
Nyenrode #VCVmarcom presentatie over social media ROIKees Romkes
Social media, we kunnen niet meer zonder. Ik, Kees Romes (van KRCC), adviseer bedrijven inmiddels al twee en een half jaar over de voordelen van social media, maar ook alles wat bij internetcommunicatie komt kijken. Twee en een half jaar, dan mag ik mezelf al bijna als expert beschouwen, zeker omdat de term eigenlijk pas een jaar of vijf echt mainstream geworden is. Ik zie mezelf echter als adviseur met mijn eigen kennis, die social media inzet als communicatietool om vaker contact te hebben en houden met mijn klanten, vrienden en familie.
Veel bedrijven vragen om de ROI van social media, mijn moeder echter nooit. Die is allang blij dat ik af en toe een foto post zodat ze weet wat ik aan het doen ben.
De zin hierboven, daar zal ik het een groot deel van de avond over hebben. Want hoe persoonlijker je het maakt, hoe meer winst je op social media kan behalen. Niet dat ik je vraag alles te delen, maar wel om het persoonlijk te maken.
Daarna maak ik de stap naar corporate strategie en gaan we op grotere schaal kijken wat van belang is en nog belangrijker, wat je er mee kan bereiken door op de juiste momenten social media in te schakelen en de resultaten te meten.
Ik hou het graag (inter)actief, vragen, hoe praktisch van aard dan ook, daar duik ik graag in. Daarom gaan we ook samen kijken naar een aantal oplossingen om activiteit te meten en te documenteren.
This document discusses best practices for creating mobile-friendly websites. It begins by noting the rise in smartphone usage and how mobile doubles the opportunities for online conversions. Key recommendations include keeping sites quick to load, simplifying navigation, optimizing designs for thumb usage, and focusing on information to aid conversions. Case studies show how sites like Kiddicare implemented practices like seamless experiences across devices and simplified navigation to boost traffic and conversions on mobile. The document concludes by encouraging building mobile sites to capitalize on new opportunities.
iCrossing UK: The Future of SEO is Content, Social and PPCiCrossing
As the search landscape continues to develop, brands need a view of the value SEO can deliver beyond a search ranking. Methods and tactics have moved. How well integrated are your digital marketing efforts? iCrossing UK CSO, Mark Iremonger and Head of SEO, Adam Skalak present at iStrategy London, November 2012.
wyeth UBS Global Life Sciences Conferencefinance12
Greg Norden, CFO of Wyeth, presented at the UBS Global Life Sciences Conference on September 25, 2007. He discussed Wyeth's strong financial performance in the second quarter and first half of 2007, with 10% revenue growth and earnings per share increases of 13-12%. Norden highlighted several of Wyeth's key marketed products that contributed significantly to revenue growth, including Enbrel, Prevnar, Effexor, and Nutritionals. He also provided an outlook for 2007 with raised EPS guidance and expectations for continued bottom line growth outpacing revenue growth.
wyeth Citi Investment Research Global Healthcare Conferencefinance12
This document summarizes Greg Norden's presentation at the 2008 Citi Investment Research Global Healthcare Conference on May 21, 2008. It discusses Wyeth's financial guidance for 2008, performance in the first quarter of 2008, key product growth drivers, focus on driving international growth, pipeline of new products in development, and initiatives to sharpen focus and manage costs through Project Impact. The presentation outlines Wyeth's strategy to position itself for future growth through a diversified business, new product launches, global expansion opportunities, and a proven R&D pipeline.
johnson & johnson PDF Download Presentationfinance4
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance. All three business segments - pharmaceutical, medical devices & diagnostics, and consumer - experienced sales growth.
- The presentation identifies growth drivers and pipeline advancements across J&J's businesses. It also addresses challenges from the economic environment and strategies to manage pressures in 2009.
- Looking forward, J&J will focus on growing existing businesses, building new platforms, and participating in healthcare policy to position itself for long-term leadership in an evolving industry.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered strong financial results in 2008, meeting guidance targets for sales growth and adjusted earnings per share.
- The company's three business segments - pharmaceuticals, medical devices & diagnostics, and consumer - all experienced sales growth in 2008.
- J&J is advancing its pharmaceutical, medical device, and consumer product pipelines with numerous new product filings planned for 2009-2010.
- While macroeconomic uncertainties may impact 2009 performance, J&J is well positioned due to its diversified business portfolio and continued investment in R&D and new product development.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance despite challenges.
- Consumer and Medical Devices & Diagnostics saw sales growth while Pharmaceutical sales declined due to patent expirations.
- The company is focusing on new product launches, emerging markets, and cost reductions to address current economic pressures.
- J&J's strategic focus is on winning in healthcare through R&D, new growth platforms, and participation in public policy to shape the evolving healthcare environment.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered sales growth of 4.3% in 2008 and exceeded earnings guidance. All three business segments - pharmaceutical, medical devices & diagnostics, and consumer - experienced sales growth.
- The presentation identifies growth drivers and pipeline advancements across J&J's businesses. It also addresses challenges from the economic environment and strategies to manage pressures in 2009.
- Looking forward, J&J will focus on growing existing businesses, building new platforms, and participating in healthcare policy to "win in healthcare" over the long term.
Jean-Marc Huët, Senior Vice President and Chief Financial Officer of Bristol-Myers Squibb, presented at the Credit Suisse Health Care Conference on November 13, 2008. He discussed Bristol-Myers Squibb's plans to become a next generation biopharma company through productivity initiatives aimed at improving efficiency. He highlighted strong financial performance in 2008 due to sales growth, margin improvements, and portfolio shifts including selling medical devices businesses. Huët believes Bristol-Myers Squibb is well positioned with a strong cash position and conservative capital structure to execute on productivity goals and pipeline investments.
- The document discusses Quest Diagnostics' strong financial performance in 2008, with 8.1% revenue growth and 14% earnings growth.
- It achieved 0.6% operating margin expansion and $1.1 billion in operating cash flow.
- Quest Diagnostics also saw accomplishments in expanding its medical leadership, enhancing the patient experience, and leveraging its unparalleled assets.
johnson & johnson Q4 2008 Investor Relations Business Overview finance4
This document contains a safe harbor statement for Johnson & Johnson noting that the press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It also provides a list of specific risks and uncertainties the company faces and directs readers to further information in the company's annual report. The statement does not guarantee the company's financial performance but aims to fairly advise investors and analysts of known risks.
Sanofi-Aventis reported its Q1 2009 results. The company delivered strong underlying sales growth of flagship products and vaccines. R&D transformation efforts are ongoing, including a thorough portfolio review that led to the discontinuation of several clinical projects. Key pipeline programs discussed include aflibercept, a VEGF Trap in Phase III studies for various cancers, and BSI-201, a potential first-in-class PARP inhibitor in a Phase IIb trial for triple negative breast cancer. Sanofi reiterated its guidance for over 7% adjusted EPS growth in 2009 at constant exchange rates, barring major adverse events.
cardinal health Q3 2008 Earnings Presentationfinance2
The document summarizes Cardinal Health's Q3 FY2008 earnings call. It includes opening remarks from the CEO and CFO. The CFO provides an overview of Q3 financial results including revenue growth of 5% and EPS growth of 13%. Segment results are also summarized, with Healthcare Supply Chain Services facing challenges from repricings and controlled substance regulations while Medical Products and Technologies saw growth from acquisitions. Clinical Technologies and Services saw continued strong performance. Full year guidance targets the mid-point of $3.75-3.85 EPS, excluding a small dilution from a recent acquisition.
rad T. Sauer Executive Vice President, Health Care Businessfinance10
3M's health care business has experienced strong growth in recent years. To continue this growth, 3M is pursuing strategies like reconfiguring its health care portfolio to focus on areas of strength, redirecting resources towards high growth areas, and rapidly expanding in developing countries through new products, sales coverage and manufacturing. 3M will also drive organic growth through increased R&D investment, acquisitions that bring synergies, and penetrating new market spaces like digital dentistry and food safety testing.
bristol myerd squibb Merrill Lynch Global Pharmaceutical Conferencefinance13
Jean-Marc Huët, Senior Vice President and Chief Financial Officer of Bristol-Myers Squibb, presented at the Merrill Lynch Global Healthcare Conference in London on September 16, 2008. He discussed Bristol-Myers Squibb's transition of its portfolio through acquisitions and sales of companies in 2008. Huët also highlighted strong sales growth and improving margins in the second quarter of 2008 driven by top products like Plavix, Abilify, and Orencia. Finally, he laid out Bristol-Myers Squibb's strategy to deliver growth in three stages through commercial execution, productivity initiatives, and progressing its pipeline of potential new drugs.
This document summarizes Quest Diagnostics' presentation at the 26th Annual JPMorgan Healthcare Conference in January 2008. It discusses Quest Diagnostics' leadership position in the diagnostic testing market, its consistent strong growth, expanding market leadership, focus on higher growth segments, and strategy to drive further profitable growth through initiatives like reducing costs by $500 million and expanding its geographic reach.
This document provides an overview of the 26th Annual JPMorgan Healthcare Conference and Quest Diagnostics. It discusses that Quest Diagnostics is the leader in providing diagnostic testing and healthcare insights and solutions in the US, touching over 150 million patient lives each year. It also summarizes Quest Diagnostics' strategy to drive continued profitable growth through expanding usage of services, increasing electronic connectivity and access, leading medical innovation, and being the leader in cancer diagnostics.
Pfizer at Citi Global Health Care Conferencefinance5
The document is a presentation from Pfizer's CFO at a healthcare conference in May 2008. It summarizes Pfizer's strategies to: 1) maximize revenues from existing, new, and diverse product sources; 2) establish a lower, more flexible cost base; and 3) innovate its business model. The presentation provides details on optimizing Pfizer's patent-protected portfolio, capitalizing on established products, growing in emerging markets, proven cost management track record, and 2008 financial guidance.
cardinal health Conference Call Presentationfinance2
This document contains the key details from Cardinal Health's Q1 FY2009 investor call on October 29, 2008. It discusses Cardinal's financial results for Q1, including revenue of $24.3 billion (up 11% year-over-year) and operating earnings of $426 million (down 13% year-over-year). It also provides updates on Cardinal's Healthcare Supply Chain Services and Clinical and Medical Products segments. The document outlines Cardinal's financial goals for FY2009 and assumptions, and addresses questions from analysts on the call.
Cardinal Health Q2 2009 Earnings Presentationfinance2
This document contains:
1) An overview of Cardinal Health's Q2 FY2009 earnings results, reporting 8% revenue growth and mixed results across business segments.
2) Comments from executives on the Healthcare Supply Chain Services and Clinical and Medical Products segments, noting challenges from capital spending deferrals.
3) Cardinal Health's financial goals for FY2009, which include 6-7% revenue growth and $3.50-$3.60 non-GAAP EPS.
Wiekang Biotech Investor Presentation, June 2010GeoInvesting LLC
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
This document summarizes a presentation made by Quest Diagnostics at the Cowen and Company Health Care Conference on March 18, 2008. It outlines Quest Diagnostics' position as the leader in diagnostic testing in the US, its strategy to drive profitable growth through expanding its diagnostic scope and geographic reach, and its goals of being the undisputed world leader in diagnostic testing and information services while profitably growing above industry rates. It also discusses leveraging assets and capabilities, reducing costs by $500 million, and focusing on margin expansion and earnings growth in 2008-2009.
Similar to wyeth J.P. Morgan 26th Annual Healthcare Conference (20)
View Summary Manpower Inc. Withdraws Fourth Quarter 2008 Guidance 12/22/2008finance12
Manpower Inc. withdrew its fourth quarter 2008 guidance due to continued declines in the global labor markets and changes in foreign currencies. The company experienced a 20% revenue decline in the two months ended November 30, 2008 compared to the prior year. As a result of the weaker operating environment, Manpower Inc. will take restructuring charges related to employee severance and office closures in the fourth quarter. Despite the economic challenges, the company's liquidity and financial strength remains strong with $675 million in cash and $182 million in net debt as of the end of November.
The document is the 1999 annual report of Manpower Inc. It discusses the company's financial highlights for 1999, including increased systemwide sales, revenues, and operating margin compared to previous years. It summarizes the company's strategies to focus on providing workforce solutions, investing in technology, improving efficiency, and expanding in professional and specialty staffing. The report discusses how these strategies helped drive growth while improving profitability in 1999.
Manpower provided staffing solutions for a variety of clients around the world in 2000. Some key examples include:
1) Manpower Venezuela used a performance-based compensation model to win staffing contracts for three call centers in Venezuela.
2) In Australia, the Defense Force outsourced its military recruitment to Manpower due to their ability to provide a full-service solution.
3) In North Carolina, Manpower's workforce program helped IBM achieve significant contractor staffing cost savings.
This document highlights Manpower's global reach and ability to customize staffing solutions to meet the diverse needs of clients around the world.
The document is Manpower Inc.'s 2001 annual report. It summarizes that in 2001:
- Systemwide sales decreased 5.3% to $11.8 billion due to a weaker global economy and strengthening US dollar.
- Revenues decreased 3.3% and operating profit declined 23.6% as revenue growth slowed but investments continued.
- Earnings per share decreased 27% to $1.62 primarily due to currency exchange impacts. The company remained focused on providing skilled employees and workforce solutions to customers during economic uncertainty.
The document discusses Manpower's performance and strategies during a period of economic uncertainty in 2002. It summarizes that Manpower strengthened its financial position, improved efficiency, expanded services, and increased customer relationships despite challenging market conditions. Manpower emerged stronger and confident in its leadership position. The speed of work increased pressure on companies, but Manpower provided flexibility and quality service to help customers.
This document contains a long list of place names from around the world arranged in no clear order. The places span multiple continents and countries, including locations in France, Italy, Germany, Japan, Canada, Mexico, Argentina and many others.
The document is Manpower Inc.'s 2004 annual report. It discusses Manpower's 57-year history of providing temporary staffing solutions and how it has expanded its services over time. It also discusses how the world of work is constantly changing and how Manpower continues to adapt its solutions to help clients with their HR strategies and market competition. The report features perspectives from clients, including IBM's vice president of global talent discussing how IBM partners with Manpower for just-in-time talent management to source skills globally on demand.
This document is Manpower Inc.'s 2005 annual report. It summarizes the company's financial performance for 2005, noting revenues exceeded $16 billion, a 7.7% increase over 2004. Net income increased 8% to $260 million. It also discusses strategic moves taken in 2005 to expand operations in emerging markets like China and India. Finally, it describes the company's rebranding effort, launching a new logo and tagline - "What do you do?" - to reflect its expanded services beyond temporary staffing.
Manpower Inc. reported record financial results in 2006. Revenues increased 10.8% to $17.6 billion and net earnings increased 53% to $398 million. The company's stock price rose 61% in 2006, outperforming the broader market. Operating profit increased 24% to $532 million due to growth in business and effective cost management across regions. The company has transitioned to focus on providing a wider range of employment services beyond temporary staffing alone. The rebranding launched in 2006 aligned the company's image with this strategic transition and positioned Manpower for continued strong performance.
Manpower Inc. had record revenues and earnings in 2007. Revenues increased 17% to $20.5 billion while net earnings grew 22% to $484.7 million. The company has diversified its services over the past decade to include specialty services beyond temporary staffing, such as permanent recruitment and leadership development. This has improved profit margins and reduced sensitivity to economic cycles. Investments in new services like recruitment process outsourcing have positioned Manpower for continued growth.
The document is a Form 8-K filed by The Goodyear Tire & Rubber Company with the SEC on May 22, 2007. It announces that the company entered into an underwriting agreement to sell over 22 million shares of its common stock in a public offering at $33 per share, for total proceeds of over $750 million. The underwriters exercised their option to purchase additional shares. The company's general counsel issued a legality opinion on the shares offering. The proceeds will be used for general corporate purposes.
The Goodyear Tire & Rubber Company issued notices to partially redeem outstanding notes. It will redeem $140 million of its 9% Senior Notes due 2015 at 109% of par value, and $175 million of its 8.625% Senior Notes due 2011 at 108.625% of par value. Both redemptions will occur on June 29, 2007. Goodyear is using proceeds from a recent equity offering of common stock to fund the redemptions, as allowed under provisions permitting redemption of up to 35% of notes with equity offering proceeds.
Neither of excess is good for the society, it has to be balanced to achieve maximum social benefit. Dalton called this principle as "Maximum Social Advantage" and Pigou termed it as "Maximum Aggregate Welfare". It was introduced by Swedish Economist "Erik Lindahl in 1919". See my ppt for additional details.
Public Expenditure & its Classifications, Canons, Causes, Effects & Theories....Dr T AASIF AHMED
The meaning, classifications, canons, theories, effects, and trends in public spending are all included in this ppt. This has been prepared to aid students in understanding and help them achieve the best grade possible. Kindly provide your insightful opinions and recommendations. For additional details, get in touch with Dr. T. Aasif Ahmed.
The JD Euroway and Fritzgerald Zephir (Fritz) Financial Debacle.pptxsonalisaini008
In an astonishing series of events, Finance JD Euroway Inc. and its CEO Fritzgerald Zephir (Fritz) find themselves embroiled in a high-stakes legal battle, accused of orchestrating a fraudulent investment scheme.
Vaishali @ℂall @Girls ꧁❤ 9711199012 ❤꧂Fabulous sonam Mehra Top Model Safe
wyeth J.P. Morgan 26th Annual Healthcare Conference
1. J.P. Morgan 26th Annual
Healthcare Conference
Justin R. Victoria
Vice President, Investor Relations
Joseph S. Camardo, M.D.
Senior Vice President Global Medical Affairs
and North American Medical Director, Wyeth
Pharmaceuticals
January 8, 2008
2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-
looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, the
impact of competitive or generic products, product liability and other types
of lawsuits, the impact of legislative and regulatory compliance and
obtaining approvals, and patent, and other risks and uncertainties,
including those detailed from time to time in Wyeth’s periodic reports,
including quarterly reports on Form 10-Q and the annual report on Form 10-
K, filed with the Securities and Exchange Commission. Quarterly results, in
particular, can vary due to issues which include, but are not limited to,
changes in exchange rates, the timing of actions taken by the Company to
ensure long-term improvements to our manufacturing processes, the
timing of regulatory approval of new products and/or facilities and the
timing of promotional programs. Actual results may vary materially from
the forward-looking statements. The Company assumes no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.
2
4. Wyeth Performance: 3rd Quarter and Nine
Months 2007 - Key Financial Elements*
3Q 2007 YTD 2007
Net Revenue +9% +10%
Gross Margin 73.2% 73.3%
SG&A Expense +8% +4%
R&D Expense +5% +9%
Operating Profit +14% +18%
Tax Rate 29.6% 29.3%
$0.90 $2.74
Diluted Earnings Per Share
+7% +10%
*Adjusted to Exclude Certain Significant Item. See Press Release Issued October 18, 2007
4
5. Marketed Products
Strong Performance For Nine Months 2007
Enbrel +22%
$2.4 B (Amgen) $1.5 B (Wyeth) $3.9 B
Effexor +1%
$2.8 B
Prevnar +29%
$1.9 B
Protonix +5%
$1.4 B
YTD 2007 Pharma
Nutritionals +18%
$1.1 B
Revenue +11%
Alliance Rev. 0%
$973 M
Zosyn +17%
$845 M
Biotech
Premarin Biotech Now
+0%
$791 M Revenues +26%
Represents 36%
YTD 07
BeneFIX +16%
$304 M
of Total Pharma
BMP-2 $284M +23% Revenues
Rapamune +8%
$265 M
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500
(in millions)
5
6. Key Franchises – Growth Drivers
Supported by New Data
*
Helping Patients Live Life Less
First-in-Class Pneumococcal n
n
Interrupted by Their Condition
Conjugate Vaccine
(RA, JRA, Psoriasis, Psoriatic
Launched in 86 Countries
n
Arthritis and Ankylosing
Tens of Millions of Children
n Spondylitis)
Immunized and Thousands of
Extensive Safety/Efficacy and
Lives Saved n
14 Years of Clinical Experience
6 *Source: IMS Midas Audited Sales for Enbrel – Rolling Four Quarter Period Ending 3Q07
7. Wyeth’s Current/Near Term Opportunities:
Approved, in Review and Upcoming
Key
Recent FDA Pending FDA Pending
Upcoming
Further Trials
Approvals Approval
Submissions
Viviant™ Aprela™
Pristiq™
Lybrel ™ Osteoporosis Prevention Menopausal Symptoms &
Vasomotor Symptoms
& Treatment Osteoporosis
Torisel ™ Pristiq™ Bifeprunox Methylnaltrexone
Depression (I.V.)
Prevnar 13v
Tygacil™
Methylnaltrexone
Infant
(Subcutaneous) (HAP)
ReFacto® AF Prevnar 13v
Adult
Tygacil™
(CAP)
7
8. Prevnar 13v – Expanding the Coverage
Infant Adult
Provide Broadest Coverage Provide First and Only Conjugate
Vaccine That Offers Adults, Age
Available for the Global Protection
50 and Above, an Opportunity to
of Children Against Pneumococcal
Opportunity Prevent Pneumococcal
Disease
Pneumonia for the Rest of Their
Lives
Phase 2 Proof of Concept Proof of Concept Achieved
n n
Achieved
Licensing Criteria Agreed
n
Licensing Criteria Agreed Upon Upon
n
Status Worldwide Phase 3 Studies Worldwide Phase 3 Studies
n n
Ongoing Ongoing
Submission Early 2009 Submission Late 2009
n n
> $3 Billion > $1.5 Billion
Peak Sales
8
9. Confidence in Future Growth
New Data and Ongoing Stream of Phase IV Studies
COMET Is the First in a Series of Phase IV Studies to
n
Be Released in the Next Few Years
COMET Evaluated Enbrel/Methotrexate Combination
n
for Patients With Early Severe Rheumatoid Arthritis
COMET Is First Major Study With Clinical Endpoint of
n
RA Remission
COMET Demonstrated Excellent Activity to Reduce
n
Disease Activity, Improve Health Associated Quality of
Life, and Improve Work Productivity
COMET – COmbination of Methotrexate and ETanercept in Active Early
Rheumatoid Arthritis
9
10. COMET: Enbrel/Methotrexate Induces
Remission and Low Disease Activity (LDA)
80 Methotrexate (n=263)
Enbrel + Methotrexate (n=265)
64 *
50%
60 Remission
50 *
% of Subjects
41
40
28
20
0
DAS28 Remission DAS28 LDA
At One Year
*p<0.001
DAS28 = Mean Disease Activity Score
10
11. Wyeth’s Current/Near Term Opportunities:
Approved, in Review and Upcoming
Key
Recent FDA Pending FDA Pending
Upcoming
Further Trials
Approvals Approval
Submissions
Viviant™ Aprela™
Pristiq™
Lybrel ™ Osteoporosis Prevention Menopausal Symptoms &
Vasomotor Symptoms
& Treatment Osteoporosis
Torisel ™ Pristiq™ Bifeprunox Methylnaltrexone
Depression (I.V.)
Prevnar 13v
Tygacil™
Methylnaltrexone
Infant
(Subcutaneous) (HAP)
ReFacto® AF Prevnar 13v
Adult
Tygacil™
(CAP)
11
12. Interferon: Escalating to
R
18 MU SC TIW n = 207
A
626 Patients With
N
Advanced D
Metastatic RCC Torisel ™: 25 mg IV QW
O
With Poor-Risk M n = 209
Features I
Z
Torisel: 15 mg IV QW
E
+ Interferon: 6 MU SC TIW
n = 210
Hudes et al. NEJM. 2007; 356: 2271-2281. Data on File, Wyeth Research.
12
13. Allows Patients to Live Longer
Primary Efficacy Analysis (446 Deaths)
Interferon
Torisel Interferon
+ Torisel
Patients 209 207 210
# Deaths 143 149 152
Median Overall
10.9 mo 7.3 mo 8.4 mo
Survival
% Improvement in
49% 15%
Survival
Log Rank p-Value
0.0078 0.6965
Stratified
Hudes et al. NEJM. 2007; 356: 2271-2281. Data on File, Wyeth Research.
13
14. As Important As Survival: Torisel™ Is Safe
and Well Tolerated in Patients
Common Side Effects: Mucositis, Anemia,
n
Hyperlipidemia, Rash, Infection
4Treatable and Most Often Did Not Require Dose Modification
Fewer Patients Were Discontinued Due to
n
Side Effects Relative to Interferon (18% vs. 30%)
Fewer Patients Had Serious Side Effects Relative to
n
Interferon (38% vs. 48%)
Fewer Patients Required Dose Reduction Relative to
n
Interferon (20% vs. 38%)
14
15. Torisel™ Phase IV: How to Improve Outcomes in
Patients Who Need Second-Line Treatment
Study 404
Torisel 25 mg IV
R
A Weekly (n=220)
N
Second-Line D
mRCC 1:1
O
Sutent Failures M
Nexavar 400 mg
I
PO bid (n=220)
Z
E
Global Trial With Patient Enrollment
In U.S. Sites Currently Underway
15
16. Torisel™ Has Significant Potential for
Expanded Medical Impact and Growth
Torisel Is the Only New Drug for Renal Cell Cancer
n
Proven to Extend Survival
n Study 404 in Second-Line Sutent Failures Currently
Enrolling
4Data Will Be Available in 2009
4Second-Line Use Represents ~50% of Projected 2010 Sales
Registration for Mantle Cell Lymphoma Was Submitted
n
in Europe in December 2007
Torisel Peak Sales > $500 Million
16
17. Torisel™ Will Be Followed by Other New
Drugs From the Strong Oncology Pipeline
Phase 3 Started for Two Products in December 2007
n
4CMC-544: Targeted Calicheamicin Conjugate for Follicular Lymphoma
4SKI-606 (Bosutinub): Targeted Kinase Inhibitor for Chronic Myelogenous
Leukemia
- This Is a Comparative Study With Gleevec for First-Line Treatment
Phase 2 Is Completing for Next Oncology Product
n
4HKI-272: New Kinase Inhibitor for Breast Cancer
17
18. Wyeth’s Current/Near Term Opportunities:
Approved, in Review and Upcoming
Key
Recent FDA Pending FDA Pending
Upcoming
Further Trials
Approvals Approval
Submissions
Viviant™ Aprela™
Pristiq™
Lybrel ™ Osteoporosis Prevention Menopausal Symptoms &
Vasomotor Symptoms
& Treatment Osteoporosis
Torisel ™ Pristiq™ Bifeprunox Methylnaltrexone
Depression (I.V.)
Prevnar 13v
Tygacil™
Methylnaltrexone
Infant
(Subcutaneous) (HAP)
ReFacto® AF Prevnar 13v
Adult
Tygacil™
(CAP)
18
19. Pristiq™ Is Effective for Treating Depression
at 50mg
HAM-D17 - Adjusted Mean Total Scores Over Time
Study 333
25
Placebo
DVS SR 50 mg
DVS SR 100 mg
Adjusted Mean Total Score
20
Final
15
(LOCF)
a,b
10
a : p-Value DVS 50mg vs. placebo <= 0.05
b : p-Value DVS 100mg vs. placebo <= 0.05 a,b a,b
a,b
0 2 4 6 8 Endpoint
Time (Weeks)
Presented December 12, 2007
19
20. Pristiq™: Nausea Is Limited to the Early Part
of the Treatment Period
Study 333
25 Placebo
% Patients Reporting Nausea as Treatment
DVS SR 50 mg
20 DVS SR 100 mg
Emergent Adverse Event
15
10
5
0
Day 1-7 Day 8- Day 15- Day 22- Day 29- Day 43- Day > Post
14 21 28 42 56 56 study
20
21. Pristiq™ Tolerability – Nausea
Nausea - Tolerability Issue Common to SNRI Class
n
n Occurs in About 1/5 of Patients Treated with Pristiq
50 mg – Low Rate
4Nausea Incidence in Combined Study Data for 50 mg Is 22% (vs. 11%
Placebo)
- Two Low Dose (50 mg) Fixed Dose Studies
4Compared to Nausea Incidence of 35% to 41% in Previously Reported
Fixed Dose Studies 100 to 400 mg
Nausea Is Mostly Mild or Moderate
n
n Abates in About One Week
n Does Not Lead to Excess Discontinuation of Therapy
n Allows Patients to Tolerate the Drug and Get the
Antidepressant Benefit of the Treatment
21
22. Low Dose Program for Pristiq™ – A Strong
Addition to the NDA Database for Launch
Efficacy
n
4Replicate Evidence of Efficacy at 50 mg and 100 mg
4Efficacy Observed As Early As Week 4 for Both Doses
- Comparable to Current Antidepressant Therapy
Safety
n
4Reduced Adverse-Event Related Discontinuation Withdrawal Rates
Compared With Higher Doses
4Improvement in Incidence of Nausea and Overall Tolerability
4No New Safety Signals Seen in Labs, Vital Signs or ECG Parameters
Pristiq MDD NDA Action Date – End February 2008
22
23. Wyeth’s Current/Near Term Opportunities:
Approved, in Review and Upcoming
Key
Recent FDA Pending FDA Pending
Upcoming
Further Trials
Approvals Approval
Submissions
Viviant™ Aprela™
Pristiq™
Lybrel ™ Osteoporosis Prevention Menopausal Symptoms &
Vasomotor Symptoms
& Treatment Osteoporosis
Torisel ™ Pristiq™ Bifeprunox Methylnaltrexone
Depression (I.V.)
Prevnar 13v
Tygacil™
Methylnaltrexone
Infant
(Subcutaneous) (HAP)
ReFacto® AF Prevnar 13v
Adult
Tygacil™
(CAP)
23
24. Methylnaltrexone: Significant Unmet Medical Need in
Opioid Induced Constipation and Post Operative Ileus
Opioid Induced Constipation (OIC)
A Common Side Effect That Can Be a Barrier to Effective Pain
n
Management
First Indication for Methylnaltrexone Will Be for Treatment of OIC
n
in Patients Receiving Palliative Care
Studies Ongoing for OIC Patients With Chronic Non-Malignant
n
Pain, and for Shorter Term Acute Pain That Requires Opiates,
e.g. Post-Operative OIC in Orthopedic Surgical Patients
Post Operative Ileus (POI)
A Complication of Surgery That Delays Recovery and Can Extend
n
Hospital Stay
No Medicines Approved to Treat POI
n
24
25. Importance of Opiates for Pain Creates Substantial
Opportunity for Innovative New Product
In U.S. 5 Million Patients Have Opioid Induced
Constipation
>40% Patients
~12M Patients OIC
Continuous or Population
Experience
Long-Term Use† (Est.)
OIC
4.6M
5.0
Continuous Use
Million
Patients
7.2M
Long-Term Use
(Wyeth Estimates)
† Longitudinal Patient Data – Opioid Use Days Per Annum: Short -Term = <60 days, Long-Term = 61 – 300 days, &
Continuous = 300+ days
25
26. Methylnaltrexone Is a Peripherally Selective
Opioid Antagonist
CH3
Opioids Activate Receptors
Morphine Acts Centrally
in the Brain and Provide n
Pain Relief…
N and Peripherally
Morphine
n Methylnaltrexone Is a Mu
Opioid Receptor
Antagonist
HO O OH n Does Not Cross the
Blood-Brain Barrier
n Antagonizes Peripheral,
CH3
but Not Central Opioid
Receptors
Methylnaltrexone
N+
n Reverses Opioid Induced
Constipation Without
HO
Reversing Analgesia or
Inducing Withdrawal
… But Receptor Activation
in the GI Tract Results in
HO O O
Constipation.
26
27. Methylnaltrexone Is Effective in Relieving
Constipation in Patients Who Need Opiates
>50% of Patients Have Bowel Movement
Within 4 Hours (Study 301)
70
Subcutaneous Methylnaltrexone
% Patients Having Bowel Movement
60
50
40
30
20
10
0
Placebo 0.15 mg/kg 0.30 mg/kg
Recommended Dose
27
28. Methylnaltrexone Induces a Rapid and
Predictable Response in OIC
Study 301
Subcutaneous Methylnaltrexone
75%
30 minutes
0.30 mg/kg
% Patients Having
Bowel Movement
0.15 mg/kg
50%
25%
Placebo
0%
0 4
1 2 3 5
Hours
Recommended Dose
28
29. Methylnaltrexone IV Accelerates Recovery in
Post Operative Ileus (POI): Phase 2 Data
65 Patients With Segmental Colectomies
n
Randomized to Methylnaltrexone IV or Placebo
n
Evaluated for Clinical Signs Indicating Recovery of Bowel Function and
n
Readiness for Discharge
Acceleration
Time to Post-operative Recovery Endpoint (On Average)
Tolerance of First Solid Meal (p=0.12) 25 Hours
First Bowel Movement (p=0.01) 23 Hours
Discharge Eligibility 30 Hours
(p=0.03)
Actual Discharge 25 Hours
(p=0.09)
Discharge a Day Early
29
30. Methylnaltrexone: Status Summary
Subcutaneous Product for Palliative Care
n
4NDA Action Date January 30, 2008
4European Marketing Application Submitted May 2007
Intravenous Phase 3 Studies To Complete in 1Q08
n
4Two Studies of Post Operative Ileus
4NDA Submission Planned For Mid 2008
Oral Formulation – Phase 2
n
4Two Studies in OIC Patients with Chronic Non-Malignant Pain
Additional Phase 3 and Phase 4 Studies for
n
Subcutaneous Product in OIC
4Chronic Non-Malignant Pain
4Post-Operative OIC in Orthopedic Surgical Patients
30
31. Wyeth R&D: New Drugs With Important
Indications
Launched:
Tygacil® Complicated Skin & Abdominal Infections
Torisel™ Renal Cell Cancer
Lybrel™ Contraception
Late Stage Pipeline Includes:
Pristiq ™ Major Depressive Disorder
Viviant™ Prevention/Treatment Osteoporosis
Methylnaltrexone SC – Opioid Induced Constipation
IV – Post Operative Ileus
Tygacil® CAP/HAP
Aprela ™ Menopausal Symptoms/Osteoporosis
Pristiq ™ Menopausal Symptoms
Prevnar 13 Infant/Adult Invasive Pneumococcal Disease
Bifeprunox Schizophrenia Maintenance
Bapineuzumab Alzheimer’s Disease
31
32. Wyeth R&D: New Drugs With Important
Indications
Launched:
Tygacil® Complicated Skin & Abdominal Infections
Torisel™ Renal Cell Cancer
Lybrel™ Contraception
Late Stage Pipeline Includes:
Pristiq ™ Major Depressive Disorder
Viviant™ Prevention/Treatment Osteoporosis
Methylnaltrexone SC – Opioid Induced Constipation
IV – Post Operative Ileus
Tygacil® CAP/HAP
Aprela ™ Menopausal Symptoms/Osteoporosis
Pristiq ™ Menopausal Symptoms
Prevnar 13 Infant/Adult Invasive Pneumococcal Disease
Bifeprunox Schizophrenia Maintenance
Bapineuzumab Alzheimer’s Disease
32
33. Bapineuzumab Phase 3 for Alzheimer’s
Disease
Four Studies in Over 4,000 Patients Are Beginning
n
Worldwide
4First U.S. Patient Enrolled December 2007; International Studies to Initiate
Early 2008
4Patients Are Stratified by APO E-4 Carriers vs. Non-Carriers
4APO E-4 Carriers
- 0.5mg/kg vs. Placebo
- Minimize Occurrence of Vasogenic Edema
4APO E-4 Non-Carriers
- 0.5 mg/kg, 1.0 mg/kg and 2.0 mg/kg vs. Placebo
Co-Primary Efficacy Endpoints – Validated Cognitive
n
and Functional Scales
4Other Cognitive, Functional, Behavioral, Biomarkers, Health Outcomes
Endpoints
Phase 2 Data Mid-2008
n
33
34. Conclusion
Strong Growth Drivers in the Market
n
Successful New Product Launches
n
A Series of New Products Pending Approval
n
Innovative Therapies in Development To Address A Number
n
of High Unmet Medical Needs with Significant Commercial
Potential
34